CRA has provided economic assessments of competition in connection with several mergers of clinical laboratories. CRA has analyzed the degree of competition from hospital and physician-owned labs, the nature of bidding for capitated lab arrangements with providers, and the extent to which a national market exists for contracts with health plans exists.
What’s 340B? An economist’s view of the recent wave of 340B litigation
But this change has led to complex relationships among pharmaceutical manufacturers, hospitals, pharmacies, and third-party administrators, increasing...